Skip to main content

Vaxcyte

Vaxcyte Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation conjugate vaccines designed to prevent bacterial infectious diseases, prominently featuring its lead vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease. The company utilizes advanced protein engineering, synthetic chemistry, and carrier protein technologies to develop vaccines providing broader protection against complex bacterial strains. Its core business operations encompass biopharmaceutical research, vaccine formulation engineering, clinical trial execution, and pharmaceutical product development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic research collaborations. Vaxcyte holds a pioneering market position in advanced bacterial vaccine engineering. The company is headquartered in San Carlos, California, United States, and its common stock trades on the Nasdaq Global Select Market.

9 of the funds FundTelligence covers report a position in Vaxcyte.

Legal name
Vaxcyte Inc
Sector
Health Care
Country
United States
Funds holding it
9

Funds holding Vaxcyte

Showing the 8 largest of 9 funds holding it.

Loading...